ViiV HEALTHCARE ANNOUNCES U.S. FDA APPROVAL OF DOVATO (DOLUTEGRAVIR/LAMIVUDINE) FOR ADOLESCENTS LIVING WITH HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the U.S. Food and Drug Administration (FDA) approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato

Please find additional informaiton to the following link: https://viivhealthcare.com/en-us/media-center/news/press-releases/2024/april/fda-approval-of-dovato/